ID   4F2_HUMAN               Reviewed;         630 AA.
AC   P08195; J3KPF3; Q13543;
DT   01-AUG-1988, integrated into UniProtKB/Swiss-Prot.
DT   01-SEP-2009, sequence version 3.
DT   28-JUN-2023, entry version 242.
DE   RecName: Full=4F2 cell-surface antigen heavy chain {ECO:0000303|PubMed:3476959};
DE            Short=4F2hc {ECO:0000303|PubMed:11557028};
DE   AltName: Full=4F2 heavy chain antigen {ECO:0000303|PubMed:3036867};
DE   AltName: Full=Lymphocyte activation antigen 4F2 large subunit {ECO:0000303|PubMed:3480538};
DE   AltName: Full=Solute carrier family 3 member 2 {ECO:0000303|PubMed:12270127};
DE   AltName: CD_antigen=CD98;
GN   Name=SLC3A2 {ECO:0000312|HGNC:HGNC:11026}; Synonyms=MDU1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), AND SUBCELLULAR LOCATION.
RX   PubMed=3476959; DOI=10.1073/pnas.84.18.6526;
RA   Quackenbush E., Clabby M., Gottesdiener K.M., Barbosa J., Jones N.H.,
RA   Strominger J.L., Speck S., Leiden J.M.;
RT   "Molecular cloning of complementary DNAs encoding the heavy chain of the
RT   human 4F2 cell-surface antigen: a type II membrane glycoprotein involved in
RT   normal and neoplastic cell growth.";
RL   Proc. Natl. Acad. Sci. U.S.A. 84:6526-6530(1987).
RN   [2]
RP   ERRATUM OF PUBMED:3476959, AND SEQUENCE REVISION.
RA   Quackenbush E., Clabby M., Gottesdiener K.M., Barbosa J., Jones N.H.,
RA   Strominger J.L., Speck S., Leiden J.M.;
RL   Proc. Natl. Acad. Sci. U.S.A. 84:8618-8618(1987).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2).
RX   PubMed=3036867; DOI=10.1016/s0021-9258(18)47972-0;
RA   Teixeira S., di Grandi S., Kuehn L.C.;
RT   "Primary structure of the human 4F2 antigen heavy chain predicts a
RT   transmembrane protein with a cytoplasmic NH2 terminus.";
RL   J. Biol. Chem. 262:9574-9580(1987).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), SUBCELLULAR LOCATION, TISSUE
RP   SPECIFICITY, AND INDUCTION.
RC   TISSUE=Fibroblast;
RX   PubMed=3480538; DOI=10.1073/pnas.84.24.9204;
RA   Lumadue J.A., Glick A.B., Ruddle F.H.;
RT   "Cloning, sequence analysis, and expression of the large subunit of the
RT   human lymphocyte activation antigen 4F2.";
RL   Proc. Natl. Acad. Sci. U.S.A. 84:9204-9208(1987).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], ALTERNATIVE SPLICING (ISOFORM 2), TISSUE
RP   SPECIFICITY, AND INDUCTION.
RX   PubMed=3265470; DOI=10.1128/mcb.8.9.3809-3819.1988;
RA   Gottesdiener K.M., Karpinski B.A., Lindsten T., Strominger J.L.,
RA   Jones N.H., Thompson C.B., Leiden J.M.;
RT   "Isolation and structural characterization of the human 4F2 heavy-chain
RT   gene, an inducible gene involved in T-lymphocyte activation.";
RL   Mol. Cell. Biol. 8:3809-3819(1988).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), FUNCTION, SUBUNIT, INTERACTION WITH
RP   SLC7A5, SUBCELLULAR LOCATION, TISSUE SPECIFICITY, AND TRANSPORTER ACTIVITY.
RC   TISSUE=Placenta;
RX   PubMed=11557028; DOI=10.1016/s0005-2736(01)00384-4;
RA   Yanagida O., Kanai Y., Chairoungdua A., Kim D.K., Segawa H., Nii T.,
RA   Cha S.H., Matsuo H., Fukushima J., Fukasawa Y., Tani Y., Taketani Y.,
RA   Uchino H., Kim J.Y., Inatomi J., Okayasu I., Miyamoto K., Takeda E.,
RA   Goya T., Endou H.;
RT   "Human L-type amino acid transporter 1 (LAT1): characterization of function
RT   and expression in tumor cell lines.";
RL   Biochim. Biophys. Acta 1514:291-302(2001).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA], AND ALTERNATIVE SPLICING
RP   (ISOFORM 4).
RX   PubMed=16554811; DOI=10.1038/nature04632;
RA   Taylor T.D., Noguchi H., Totoki Y., Toyoda A., Kuroki Y., Dewar K.,
RA   Lloyd C., Itoh T., Takeda T., Kim D.-W., She X., Barlow K.F., Bloom T.,
RA   Bruford E., Chang J.L., Cuomo C.A., Eichler E., FitzGerald M.G.,
RA   Jaffe D.B., LaButti K., Nicol R., Park H.-S., Seaman C., Sougnez C.,
RA   Yang X., Zimmer A.R., Zody M.C., Birren B.W., Nusbaum C., Fujiyama A.,
RA   Hattori M., Rogers J., Lander E.S., Sakaki Y.;
RT   "Human chromosome 11 DNA sequence and analysis including novel gene
RT   identification.";
RL   Nature 440:497-500(2006).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 3).
RC   TISSUE=Lung, and Placenta;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [10]
RP   PROTEIN SEQUENCE OF 1-17; 146-171; 227-245; 304-313; 440-451; 511-525 AND
RP   593-630, ACETYLATION AT MET-1, AND IDENTIFICATION BY MASS SPECTROMETRY.
RC   TISSUE=Cervix carcinoma;
RA   Bienvenut W.V., Lao L., Ryan K.L.;
RL   Submitted (OCT-2009) to UniProtKB.
RN   [11]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 83-209 (ISOFORM 4).
RC   TISSUE=Lung carcinoma;
RA   Strausberg R.L.;
RL   Submitted (SEP-2000) to the EMBL/GenBank/DDBJ databases.
RN   [12]
RP   PROTEIN SEQUENCE OF 112-122; 148-160; 227-245; 248-255; 288-298; 304-313;
RP   440-451; 511-524 AND 593-625, AND IDENTIFICATION BY MASS SPECTROMETRY.
RC   TISSUE=B-cell lymphoma;
RA   Bienvenut W.V.;
RL   Submitted (MAR-2005) to UniProtKB.
RN   [13]
RP   FUNCTION, SUBUNIT, SUBCELLULAR LOCATION, INTERACTION WITH SLC7A7,
RP   INHIBITION, AND MUTAGENESIS OF CYS-210 AND CYS-431.
RX   PubMed=9829974; DOI=10.1074/jbc.273.49.32437;
RA   Torrents D., Estevez R., Pineda M., Fernandez E., Lloberas J., Shi Y.-B.,
RA   Zorzano A., Palacin M.;
RT   "Identification and characterization of a membrane protein (y+L amino acid
RT   transporter-1) that associates with 4F2hc to encode the amino acid
RT   transport activity y+L. A candidate gene for lysinuric protein
RT   intolerance.";
RL   J. Biol. Chem. 273:32437-32445(1998).
RN   [14]
RP   FUNCTION, SUBUNIT, AND TRANSPORTER ACTIVITY.
RX   PubMed=9751058; DOI=10.1038/26246;
RA   Mastroberardino L., Spindler B., Pfeiffer R., Skelly P.J., Loffing J.,
RA   Shoemaker C.B., Verrey F.;
RT   "Amino-acid transport by heterodimers of 4F2hc/CD98 and members of a
RT   permease family.";
RL   Nature 395:288-291(1998).
RN   [15]
RP   FUNCTION, AND SUBUNIT.
RX   PubMed=9878049; DOI=10.1093/emboj/18.1.49;
RA   Pfeiffer R., Rossier G., Spindler B., Meier C., Kuehn L.C., Verrey F.;
RT   "Amino acid transport of y+L-type by heterodimers of 4F2hc/CD98 and members
RT   of the glycoprotein-associated amino acid transporter family.";
RL   EMBO J. 18:49-57(1999).
RN   [16]
RP   FUNCTION, SUBUNIT, AND SUBCELLULAR LOCATION.
RX   PubMed=10391915; DOI=10.1074/jbc.274.28.19738;
RA   Pineda M., Fernandez E., Torrents D., Estevez R., Lopez C., Camps M.,
RA   Lloberas J., Zorzano A., Palacin M.;
RT   "Identification of a membrane protein, LAT-2, that co-expresses with 4F2
RT   heavy chain, an L-type amino acid transport activity with broad specificity
RT   for small and large zwitterionic amino acids.";
RL   J. Biol. Chem. 274:19738-19744(1999).
RN   [17]
RP   FUNCTION, SUBUNIT, AND TRANSPORTER ACTIVITY.
RX   PubMed=10574970; DOI=10.1074/jbc.274.49.34948;
RA   Rossier G., Meier C., Bauch C., Summa V., Sordat B., Verrey F., Kuehn L.C.;
RT   "LAT2, a new basolateral 4F2hc/CD98-associated amino acid transporter of
RT   kidney and intestine.";
RL   J. Biol. Chem. 274:34948-34954(1999).
RN   [18]
RP   FUNCTION, SUBUNIT, BIOPHYSICOCHEMICAL PROPERTIES, AND INTERACTION WITH
RP   SLC7A6.
RX   PubMed=10903140; DOI=10.1042/bj3490787;
RA   Broeer A., Wagner C.A., Lang F., Broeer S.;
RT   "The heterodimeric amino acid transporter 4F2hc/y+LAT2 mediates arginine
RT   efflux in exchange with glutamine.";
RL   Biochem. J. 349:787-795(2000).
RN   [19]
RP   FUNCTION, SUBUNIT, SUBCELLULAR LOCATION, AND TRANSPORTER ACTIVITY.
RX   PubMed=11311135; DOI=10.1042/bj3550725;
RA   Broeer A., Friedrich B., Wagner C.A., Fillon S., Ganapathy V., Lang F.,
RA   Broeer S.;
RT   "Association of 4F2hc with light chains LAT1, LAT2 or y+LAT2 requires
RT   different domains.";
RL   Biochem. J. 355:725-731(2001).
RN   [20]
RP   FUNCTION, SUBUNIT, SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY.
RX   PubMed=11389679; DOI=10.1042/0264-6021:3560719;
RA   Ritchie J.W.A., Taylor P.M.;
RT   "Role of the System L permease LAT1 in amino acid and iodothyronine
RT   transport in placenta.";
RL   Biochem. J. 356:719-725(2001).
RN   [21]
RP   SUBUNIT, INTERACTION WITH BETA-1 INTEGRINS, AND MUTAGENESIS OF CYS-210 AND
RP   CYS-431.
RX   PubMed=11696247; DOI=10.1186/1471-2091-2-10;
RA   Kolesnikova T.V., Mannion B.A., Berditchevski F., Hemler M.E.;
RT   "Beta1 integrins show specific association with CD98 protein in low density
RT   membranes.";
RL   BMC Biochem. 2:10-10(2001).
RN   [22]
RP   FUNCTION, SUBUNIT, TRANSPORTER ACTIVITY, ACTIVITY REGULATION, AND
RP   BIOPHYSICOCHEMICAL PROPERTIES.
RX   PubMed=11564694; DOI=10.1210/endo.142.10.8418;
RA   Friesema E.C.H., Docter R., Moerings E.P.C.M., Verrey F., Krenning E.P.,
RA   Hennemann G., Visser T.J.;
RT   "Thyroid hormone transport by the heterodimeric human system L amino acid
RT   transporter.";
RL   Endocrinology 142:4339-4348(2001).
RN   [23]
RP   FUNCTION, SUBCELLULAR LOCATION, TISSUE SPECIFICITY, AND INDUCTION.
RX   PubMed=11742812; DOI=10.1152/ajpcell.2002.282.1.c196;
RA   Okamoto Y., Sakata M., Ogura K., Yamamoto T., Yamaguchi M., Tasaka K.,
RA   Kurachi H., Tsurudome M., Murata Y.;
RT   "Expression and regulation of 4F2hc and hLAT1 in human trophoblasts.";
RL   Am. J. Physiol. 282:C196-C204(2002).
RN   [24]
RP   INTERACTION WITH TLCD3A/CT120.
RX   PubMed=12270127; DOI=10.1016/s0006-291x(02)02227-1;
RA   He X.H., Di Y., Li J., Xie Y., Tang Y., Zhang F., Wei L., Zhang Y.,
RA   Qin W.X., Huo K., Li Y., Wan D.F., Gu J.R.;
RT   "Molecular cloning and characterization of CT120, a novel membrane-
RT   associated gene involved in amino acid transport and glutathione
RT   metabolism.";
RL   Biochem. Biophys. Res. Commun. 297:528-536(2002).
RN   [25]
RP   FUNCTION, SUBUNIT, TRANSPORTER ACTIVITY, AND ACTIVITY REGULATION.
RX   PubMed=12117417; DOI=10.1042/bj20020841;
RA   Simmons-Willis T.A., Koh A.S., Clarkson T.W., Ballatori N.;
RT   "Transport of a neurotoxicant by molecular mimicry: the methylmercury-L-
RT   cysteine complex is a substrate for human L-type large neutral amino acid
RT   transporter (LAT) 1 and LAT2.";
RL   Biochem. J. 367:239-246(2002).
RN   [26]
RP   FUNCTION, SUBUNIT, SUBCELLULAR LOCATION, TRANSPORTER ACTIVITY,
RP   BIOPHYSICOCHEMICAL PROPERTIES, AND ACTIVITY REGULATION.
RX   PubMed=12225859; DOI=10.1016/s0005-2736(02)00516-3;
RA   Kim D.K., Kanai Y., Choi H.W., Tangtrongsup S., Chairoungdua A., Babu E.,
RA   Tachampa K., Anzai N., Iribe Y., Endou H.;
RT   "Characterization of the system L amino acid transporter in T24 human
RT   bladder carcinoma cells.";
RL   Biochim. Biophys. Acta 1565:112-121(2002).
RN   [27]
RP   MASS SPECTROMETRY.
RC   TISSUE=Mammary cancer;
RX   PubMed=11840567;
RX   DOI=10.1002/1615-9861(200202)2:2<212::aid-prot212>3.0.co;2-h;
RA   Harris R.A., Yang A., Stein R.C., Lucy K., Brusten L., Herath A.,
RA   Parekh R., Waterfield M.D., O'Hare M.J., Neville M.A., Page M.J.,
RA   Zvelebil M.J.;
RT   "Cluster analysis of an extensive human breast cancer cell line protein
RT   expression map database.";
RL   Proteomics 2:212-223(2002).
RN   [28]
RP   FUNCTION, SUBUNIT, AND TISSUE SPECIFICITY.
RX   PubMed=14603368; DOI=10.1113/eph8802647;
RA   Arancibia-Garavilla Y., Toledo F., Casanello P., Sobrevia L.;
RT   "Nitric oxide synthesis requires activity of the cationic and neutral amino
RT   acid transport system y+L in human umbilical vein endothelium.";
RL   Exp. Physiol. 88:699-710(2003).
RN   [29]
RP   FUNCTION, SUBUNIT, INTERACTION WITH ICAM1, SUBCELLULAR LOCATION, AND TISSUE
RP   SPECIFICITY.
RX   PubMed=12716892; DOI=10.1074/jbc.m302777200;
RA   Liu X., Charrier L., Gewirtz A., Sitaraman S., Merlin D.;
RT   "CD98 and intracellular adhesion molecule I regulate the activity of amino
RT   acid transporter LAT-2 in polarized intestinal epithelia.";
RL   J. Biol. Chem. 278:23672-23677(2003).
RN   [30]
RP   GLYCOSYLATION AT ASN-365; ASN-381 AND ASN-424.
RX   PubMed=12754519; DOI=10.1038/nbt827;
RA   Zhang H., Li X.-J., Martin D.B., Aebersold R.;
RT   "Identification and quantification of N-linked glycoproteins using
RT   hydrazide chemistry, stable isotope labeling and mass spectrometry.";
RL   Nat. Biotechnol. 21:660-666(2003).
RN   [31]
RP   FUNCTION, AND TISSUE SPECIFICITY.
RX   PubMed=15980244; DOI=10.1167/iovs.04-1175;
RA   Tomi M., Mori M., Tachikawa M., Katayama K., Terasaki T., Hosoya K.;
RT   "L-type amino acid transporter 1-mediated L-leucine transport at the inner
RT   blood-retinal barrier.";
RL   Invest. Ophthalmol. Vis. Sci. 46:2522-2530(2005).
RN   [32]
RP   FUNCTION, SUBUNIT, TRANSPORTER ACTIVITY, AND ACTIVITY REGULATION.
RX   PubMed=15769744; DOI=10.1074/jbc.m413164200;
RA   Li S., Whorton A.R.;
RT   "Identification of stereoselective transporters for S-nitroso-L-cysteine:
RT   role of LAT1 and LAT2 in biological activity of S-nitrosothiols.";
RL   J. Biol. Chem. 280:20102-20110(2005).
RN   [33]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-381 AND ASN-424.
RC   TISSUE=Plasma;
RX   PubMed=16335952; DOI=10.1021/pr0502065;
RA   Liu T., Qian W.-J., Gritsenko M.A., Camp D.G. II, Monroe M.E., Moore R.J.,
RA   Smith R.D.;
RT   "Human plasma N-glycoproteome analysis by immunoaffinity subtraction,
RT   hydrazide chemistry, and mass spectrometry.";
RL   J. Proteome Res. 4:2070-2080(2005).
RN   [34]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17081983; DOI=10.1016/j.cell.2006.09.026;
RA   Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P., Mann M.;
RT   "Global, in vivo, and site-specific phosphorylation dynamics in signaling
RT   networks.";
RL   Cell 127:635-648(2006).
RN   [35]
RP   SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY.
RX   PubMed=16496379; DOI=10.1002/ijc.21866;
RA   Nawashiro H., Otani N., Shinomiya N., Fukui S., Ooigawa H., Shima K.,
RA   Matsuo H., Kanai Y., Endou H.;
RT   "L-type amino acid transporter 1 as a potential molecular target in human
RT   astrocytic tumors.";
RL   Int. J. Cancer 119:484-492(2006).
RN   [36]
RP   SUBCELLULAR LOCATION [LARGE SCALE ANALYSIS].
RC   TISSUE=Melanoma;
RX   PubMed=17081065; DOI=10.1021/pr060363j;
RA   Chi A., Valencia J.C., Hu Z.-Z., Watabe H., Yamaguchi H., Mangini N.J.,
RA   Huang H., Canfield V.A., Cheng K.C., Yang F., Abe R., Yamagishi S.,
RA   Shabanowitz J., Hearing V.J., Wu C., Appella E., Hunt D.F.;
RT   "Proteomic and bioinformatic characterization of the biogenesis and
RT   function of melanosomes.";
RL   J. Proteome Res. 5:3135-3144(2006).
RN   [37]
RP   PHOSPHORYLATION AT SER-406; SER-408; SER-410; SER-527 AND SER-531.
RX   PubMed=19065266; DOI=10.1371/journal.pone.0003895;
RA   Nguyen H.T.T., Dalmasso G., Yan Y., Obertone T.S., Sitaraman S.V.,
RA   Merlin D.;
RT   "Ecto-phosphorylation of CD98 regulates cell-cell interactions.";
RL   PLoS ONE 3:E3895-E3895(2008).
RN   [38]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT SER-2 (ISOFORM 2), CLEAVAGE OF
RP   INITIATOR METHIONINE [LARGE SCALE ANALYSIS] (ISOFORM 2), AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in a
RT   refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [39]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-365; ASN-381 AND ASN-506.
RC   TISSUE=Liver;
RX   PubMed=19159218; DOI=10.1021/pr8008012;
RA   Chen R., Jiang X., Sun D., Han G., Wang F., Ye M., Wang L., Zou H.;
RT   "Glycoproteomics analysis of human liver tissue by combination of multiple
RT   enzyme digestion and hydrazide chemistry.";
RL   J. Proteome Res. 8:651-661(2009).
RN   [40]
RP   GLYCOSYLATION AT ASN-424.
RX   PubMed=19139490; DOI=10.1074/mcp.m800504-mcp200;
RA   Jia W., Lu Z., Fu Y., Wang H.P., Wang L.H., Chi H., Yuan Z.F., Zheng Z.B.,
RA   Song L.N., Han H.H., Liang Y.M., Wang J.L., Cai Y., Zhang Y.K., Deng Y.L.,
RA   Ying W.T., He S.M., Qian X.H.;
RT   "A strategy for precise and large scale identification of core fucosylated
RT   glycoproteins.";
RL   Mol. Cell. Proteomics 8:913-923(2009).
RN   [41]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-365; ASN-381; ASN-424 AND
RP   ASN-506.
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19349973; DOI=10.1038/nbt.1532;
RA   Wollscheid B., Bausch-Fluck D., Henderson C., O'Brien R., Bibel M.,
RA   Schiess R., Aebersold R., Watts J.D.;
RT   "Mass-spectrometric identification and relative quantification of N-linked
RT   cell surface glycoproteins.";
RL   Nat. Biotechnol. 27:378-386(2009).
RN   [42]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-165, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [43]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [44]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT SER-2 (ISOFORM 2), PHOSPHORYLATION
RP   [LARGE SCALE ANALYSIS] AT SER-2 (ISOFORM 2), CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS] (ISOFORM 2), AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T.,
RA   Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.;
RT   "System-wide temporal characterization of the proteome and phosphoproteome
RT   of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [45]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT SER-2 (ISOFORM 2), CLEAVAGE OF
RP   INITIATOR METHIONINE [LARGE SCALE ANALYSIS] (ISOFORM 2), AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22223895; DOI=10.1074/mcp.m111.015131;
RA   Bienvenut W.V., Sumpton D., Martinez A., Lilla S., Espagne C., Meinnel T.,
RA   Giglione C.;
RT   "Comparative large-scale characterisation of plant vs. mammal proteins
RT   reveals similar and idiosyncratic N-alpha acetylation features.";
RL   Mol. Cell. Proteomics 11:M111.015131-M111.015131(2012).
RN   [46]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT MET-1, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22814378; DOI=10.1073/pnas.1210303109;
RA   Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A.,
RA   Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E., Timmerman E.,
RA   Prieto J., Arnesen T., Sherman F., Gevaert K., Aldabe R.;
RT   "N-terminal acetylome analyses and functional insights of the N-terminal
RT   acetyltransferase NatB.";
RL   Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012).
RN   [47]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-103; SER-134 AND SER-165, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [48]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [49]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-166, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25114211; DOI=10.1073/pnas.1413825111;
RA   Impens F., Radoshevich L., Cossart P., Ribet D.;
RT   "Mapping of SUMO sites and analysis of SUMOylation changes induced by
RT   external stimuli.";
RL   Proc. Natl. Acad. Sci. U.S.A. 111:12432-12437(2014).
RN   [50]
RP   INTERACTION WITH LAPTM4B, FUNCTION, SUBCELLULAR LOCATION, SUBUNIT, AND
RP   TRANSPORTER ACTIVITY.
RX   PubMed=25998567; DOI=10.1038/ncomms8250;
RA   Milkereit R., Persaud A., Vanoaica L., Guetg A., Verrey F., Rotin D.;
RT   "LAPTM4b recruits the LAT1-4F2hc Leu transporter to lysosomes and promotes
RT   mTORC1 activation.";
RL   Nat. Commun. 6:7250-7250(2015).
RN   [51]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25944712; DOI=10.1002/pmic.201400617;
RA   Vaca Jacome A.S., Rabilloud T., Schaeffer-Reiss C., Rompais M., Ayoub D.,
RA   Lane L., Bairoch A., Van Dorsselaer A., Carapito C.;
RT   "N-terminome analysis of the human mitochondrial proteome.";
RL   Proteomics 15:2519-2524(2015).
RN   [52]
RP   FUNCTION, FUNCTION (MICROBIAL INFECTION), INDUCTION BY HCV (MICROBIAL
RP   INFECTION), INDUCTION BY HYDROGEN PEROXIDE, AND INTERACTION WITH HEPATITIS
RP   VIRUS C/HCV PROTEIN E2 (MICROBIAL INFECTION).
RX   PubMed=30341327; DOI=10.1038/s41598-018-33861-6;
RA   Nguyen N.N.T., Lim Y.S., Nguyen L.P., Tran S.C., Luong T.T.D.,
RA   Nguyen T.T.T., Pham H.T., Mai H.N., Choi J.W., Han S.S., Hwang S.B.;
RT   "Hepatitis C Virus Modulates Solute carrier family 3 member 2 for Viral
RT   Propagation.";
RL   Sci. Rep. 8:15486-15486(2018).
RN   [53]
RP   X-RAY CRYSTALLOGRAPHY (2.1 ANGSTROMS) OF 212-630, SUBUNIT, MUTAGENESIS OF
RP   CYS-210, SUBCELLULAR LOCATION, AND DISULFIDE BOND.
RX   PubMed=17724034; DOI=10.1074/jbc.m704524200;
RA   Fort J., de la Ballina L.R., Burghardt H.E., Ferrer-Costa C., Turnay J.,
RA   Ferrer-Orta C., Uson I., Zorzano A., Fernandez-Recio J., Orozco M.,
RA   Lizarbe M.A., Fita I., Palacin M.;
RT   "The structure of human 4F2hc ectodomain provides a model for
RT   homodimerization and electrostatic interaction with plasma membrane.";
RL   J. Biol. Chem. 282:31444-31452(2007).
RN   [54] {ECO:0007744|PDB:6IRS, ECO:0007744|PDB:6IRT}
RP   STRUCTURE BY ELECTRON MICROSCOPY (3.30 ANGSTROMS) IN COMPLEX WITH SLC7A5,
RP   FUNCTION, SUBUNIT, TOPOLOGY, GLYCOSYLATION AT ASN-365; ASN-381; ASN-424 AND
RP   ASN-506, DISULFIDE BOND, MUTAGENESIS OF ARG-182; 234-GLN--ALA-630 AND
RP   LYS-532, AND TRANSPORTER ACTIVITY.
RX   PubMed=30867591; DOI=10.1038/s41586-019-1011-z;
RA   Yan R., Zhao X., Lei J., Zhou Q.;
RT   "Structure of the human LAT1-4F2hc heteromeric amino acid transporter
RT   complex.";
RL   Nature 568:127-130(2019).
RN   [55] {ECO:0007744|PDB:7P9U, ECO:0007744|PDB:7P9V}
RP   STRUCTURE BY ELECTRON MICROSCOPY (3.40 ANGSTROMS) OF 2-630 IN COMPLEX WITH
RP   SLC7A11, AND GLYCOSYLATION AT ASN-365; ASN-381; ASN-424 AND ASN-506.
RX   PubMed=34880232; DOI=10.1038/s41467-021-27414-1;
RA   Parker J.L., Deme J.C., Kolokouris D., Kuteyi G., Biggin P.C., Lea S.M.,
RA   Newstead S.;
RT   "Molecular basis for redox control by the human cystine/glutamate
RT   antiporter system xc.";
RL   Nat. Commun. 12:7147-7147(2021).
RN   [56] {ECO:0007744|PDB:7EPZ}
RP   STRUCTURE BY ELECTRON MICROSCOPY (3.40 ANGSTROMS) OF 2-630 IN COMPLEX WITH
RP   SLC7A11, DISULFIDE BOND, AND GLYCOSYLATION AT ASN-365; ASN-381; ASN-424 AND
RP   ASN-506.
RX   PubMed=35352032; DOI=10.1038/s41422-022-00642-w;
RA   Yan R., Xie E., Li Y., Li J., Zhang Y., Chi X., Hu X., Xu L., Hou T.,
RA   Stockwell B.R., Min J., Zhou Q., Wang F.;
RT   "The structure of erastin-bound xCT-4F2hc complexreveals molecular
RT   mechanisms underlying erastin-induced ferroptosis.";
RL   Cell Res. 32:687-690(2022).
CC   -!- FUNCTION: Component of several heterodimeric complexes involved in
CC       amino acid transport (PubMed:11557028, PubMed:9829974, PubMed:9751058,
CC       PubMed:10391915, PubMed:10574970, PubMed:11311135, PubMed:30341327).
CC       The precise substrate specificity depends on the other subunit in the
CC       heterodimer (PubMed:9829974, PubMed:9751058, PubMed:10391915,
CC       PubMed:10574970, PubMed:30867591, PubMed:10903140). The complexes
CC       function as amino acid exchangers (PubMed:11557028, PubMed:10903140,
CC       PubMed:12117417, PubMed:12225859, PubMed:30867591). The heterodimer
CC       functions as sodium-independent, high-affinity transporter that
CC       mediates uptake of large neutral amino acids such as phenylalanine,
CC       tyrosine, leucine, histidine, methionine, tryptophan, valine and
CC       isoleucine (PubMed:9751058, PubMed:11557028, PubMed:11311135,
CC       PubMed:11564694, PubMed:12117417, PubMed:12225859, PubMed:25998567,
CC       PubMed:30867591, PubMed:30341327). The heterodimer with SLC7A5/LAT1
CC       mediates the uptake of L-DOPA (By similarity). The heterodimer formed
CC       by SLC3A2 and SLC7A6 or SLC3A2 and SLC7A7 mediates the uptake of
CC       dibasic amino acids (PubMed:9829974, PubMed:10903140). The heterodimer
CC       with SLC7A5/LAT1 mediates the transport of thyroid hormones
CC       diiodothyronine (T2), triiodothyronine (T3) and thyroxine (T4) across
CC       the cell membrane (PubMed:11564694, PubMed:12225859). The heterodimer
CC       with SLC7A5/LAT1 is involved in the uptake of toxic methylmercury
CC       (MeHg) when administered as the L-cysteine or D,L-homocysteine
CC       complexes (PubMed:12117417). When associated with LAPTM4B, the
CC       heterodimer with SLC7A5/LAT1 is recruited to lysosomes to promote
CC       leucine uptake into these organelles, and thereby mediates mTORC1
CC       activation (PubMed:25998567). The heterodimer with SLC7A5/LAT1 may play
CC       a role in the transport of L-DOPA across the blood-brain barrier (By
CC       similarity). The heterodimer formed by SLC3A2 and SLC7A5/LAT1 or SLC3A2
CC       and SLC7A8/LAT2 is involved in the cellular activity of small molecular
CC       weight nitrosothiols, via the stereoselective transport of L-
CC       nitrosocysteine (L-CNSO) across the transmembrane (PubMed:15769744).
CC       The heterodimer with SLC7A10 translocates small neutral L- and D-amino
CC       acids across the plasma membrane. SLC3A2-SLC7A10 preferentially
CC       mediates exchange transport, but can also operate via facilitated
CC       diffusion (By similarity). Together with ICAM1, regulates the transport
CC       activity of SLC7A8/LAT2 in polarized intestinal cells by generating and
CC       delivering intracellular signals (PubMed:12716892). Required for
CC       targeting of SLC7A5/LAT1 and SLC7A8/LAT2 to the plasma membrane and for
CC       channel activity (PubMed:9751058, PubMed:11311135, PubMed:30867591).
CC       Plays a role in nitric oxide synthesis in human umbilical vein
CC       endothelial cells (HUVECs) via transport of L-arginine
CC       (PubMed:14603368). May mediate blood-to-retina L-leucine transport
CC       across the inner blood-retinal barrier (By similarity).
CC       {ECO:0000250|UniProtKB:P10852, ECO:0000250|UniProtKB:Q794F9,
CC       ECO:0000269|PubMed:10391915, ECO:0000269|PubMed:10574970,
CC       ECO:0000269|PubMed:10903140, ECO:0000269|PubMed:11311135,
CC       ECO:0000269|PubMed:11389679, ECO:0000269|PubMed:11557028,
CC       ECO:0000269|PubMed:11564694, ECO:0000269|PubMed:11742812,
CC       ECO:0000269|PubMed:12117417, ECO:0000269|PubMed:12225859,
CC       ECO:0000269|PubMed:12716892, ECO:0000269|PubMed:14603368,
CC       ECO:0000269|PubMed:15769744, ECO:0000269|PubMed:15980244,
CC       ECO:0000269|PubMed:25998567, ECO:0000269|PubMed:30341327,
CC       ECO:0000269|PubMed:30867591, ECO:0000269|PubMed:9751058,
CC       ECO:0000269|PubMed:9829974, ECO:0000269|PubMed:9878049}.
CC   -!- FUNCTION: (Microbial infection) In case of hepatitis C virus/HCV
CC       infection, the complex formed by SLC3A2 and SLC7A5/LAT1 plays a role in
CC       HCV propagation by facilitating viral entry into host cell and
CC       increasing L-leucine uptake-mediated mTORC1 signaling activation,
CC       thereby contributing to HCV-mediated pathogenesis.
CC       {ECO:0000269|PubMed:30341327}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=L-phenylalanine(in) = L-phenylalanine(out);
CC         Xref=Rhea:RHEA:27950, ChEBI:CHEBI:58095;
CC         Evidence={ECO:0000269|PubMed:10574970, ECO:0000269|PubMed:11557028,
CC         ECO:0000269|PubMed:11564694, ECO:0000269|PubMed:9751058};
CC       PhysiologicalDirection=right-to-left; Xref=Rhea:RHEA:27952;
CC         Evidence={ECO:0000305|PubMed:9751058};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=L-tryptophan(in) = L-tryptophan(out); Xref=Rhea:RHEA:70947,
CC         ChEBI:CHEBI:57912; Evidence={ECO:0000269|PubMed:10574970,
CC         ECO:0000269|PubMed:11557028, ECO:0000269|PubMed:11564694};
CC       PhysiologicalDirection=right-to-left; Xref=Rhea:RHEA:70949;
CC         Evidence={ECO:0000305|PubMed:11557028};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=L-histidine(out) = L-histidine(in); Xref=Rhea:RHEA:72807,
CC         ChEBI:CHEBI:57595; Evidence={ECO:0000269|PubMed:10574970,
CC         ECO:0000269|PubMed:11557028, ECO:0000269|PubMed:9751058};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=L-leucine(in) = L-leucine(out); Xref=Rhea:RHEA:73011,
CC         ChEBI:CHEBI:57427; Evidence={ECO:0000269|PubMed:10574970,
CC         ECO:0000269|PubMed:11311135, ECO:0000269|PubMed:11557028,
CC         ECO:0000269|PubMed:11564694, ECO:0000269|PubMed:12225859,
CC         ECO:0000269|PubMed:15769744, ECO:0000269|PubMed:25998567,
CC         ECO:0000269|PubMed:30867591, ECO:0000269|PubMed:9751058};
CC       PhysiologicalDirection=right-to-left; Xref=Rhea:RHEA:73013;
CC         Evidence={ECO:0000305|PubMed:9751058};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=L-isoleucine(in) = L-isoleucine(out); Xref=Rhea:RHEA:70943,
CC         ChEBI:CHEBI:58045; Evidence={ECO:0000269|PubMed:11311135,
CC         ECO:0000269|PubMed:11557028};
CC       PhysiologicalDirection=right-to-left; Xref=Rhea:RHEA:70945;
CC         Evidence={ECO:0000305|PubMed:11557028};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=L-valine(in) = L-valine(out); Xref=Rhea:RHEA:29703,
CC         ChEBI:CHEBI:57762; Evidence={ECO:0000269|PubMed:11557028};
CC       PhysiologicalDirection=right-to-left; Xref=Rhea:RHEA:29705;
CC         Evidence={ECO:0000305|PubMed:11557028};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=L-tyrosine(in) = L-tyrosine(out); Xref=Rhea:RHEA:68572,
CC         ChEBI:CHEBI:58315; Evidence={ECO:0000269|PubMed:11557028,
CC         ECO:0000269|PubMed:11564694};
CC       PhysiologicalDirection=right-to-left; Xref=Rhea:RHEA:68574;
CC         Evidence={ECO:0000305|PubMed:11557028};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=L-methionine(in) = L-methionine(out); Xref=Rhea:RHEA:70939,
CC         ChEBI:CHEBI:57844; Evidence={ECO:0000269|PubMed:11557028,
CC         ECO:0000269|PubMed:12117417};
CC       PhysiologicalDirection=right-to-left; Xref=Rhea:RHEA:70941;
CC         Evidence={ECO:0000305|PubMed:11557028};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=3,3'-diiodo-L-thyronine(out) = 3,3'-diiodo-L-thyronine(in);
CC         Xref=Rhea:RHEA:71823, ChEBI:CHEBI:176514;
CC         Evidence={ECO:0000269|PubMed:11564694};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=3,3',5-triiodo-L-thyronine(out) = 3,3',5-triiodo-L-
CC         thyronine(in); Xref=Rhea:RHEA:71811, ChEBI:CHEBI:533015;
CC         Evidence={ECO:0000269|PubMed:11564694};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=L-thyroxine(out) = L-thyroxine(in); Xref=Rhea:RHEA:71819,
CC         ChEBI:CHEBI:58448; Evidence={ECO:0000269|PubMed:11564694};
CC   -!- ACTIVITY REGULATION: The uptake of leucine, tyrosine and tryptophan is
CC       inhibited by the different iodothyronines, in particular T3
CC       (PubMed:11564694). The uptake of T3 is almost completely blocked by
CC       coincubation with leucine, tryptophan, tyrosine, and phenylalanine, or
CC       2-amino-bicyclo-(2,2,1)-heptane-2-carboxylate (BCH) (PubMed:11564694).
CC       Methionine uptake was inhibited by the L-system substrates L-leucine,
CC       BCH, L-cysteine and by the MeHg-L-cysteine complex and structurally
CC       related S-ethyl-L-cysteine (PubMed:12117417). MeHg-L-cysteine uptake is
CC       inhibited by L-methionine, L-leucine, BCH and S-ethyl-L-cysteine
CC       (PubMed:12117417). L-leucine transport is inhibited by phenylalanine,
CC       tyrosine, L-dopa, 3-O-methyldopa, a-methyltyrosine, a-methyldopa,
CC       gabapentin, triiodothyronine, thyroxine, melphalan and BCH
CC       (PubMed:12225859). L-leucine uptake was inhibited by L-CNSO
CC       (PubMed:15769744). {ECO:0000269|PubMed:11564694,
CC       ECO:0000269|PubMed:12117417, ECO:0000269|PubMed:12225859,
CC       ECO:0000269|PubMed:15769744}.
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=7.9 uM for T4 (in the presence of choline chloride)
CC         {ECO:0000269|PubMed:11564694};
CC         KM=0.8 uM for T3 (in the presence of choline chloride)
CC         {ECO:0000269|PubMed:11564694};
CC         KM=12.5 uM for reverse triiodothyronine (rT3) (in the presence of
CC         choline chloride) {ECO:0000269|PubMed:11564694};
CC         KM=7.9 uM for T2 (in the presence of choline chloride)
CC         {ECO:0000269|PubMed:11564694};
CC         KM=46 uM for leucine (in the presence of choline chloride)
CC         {ECO:0000269|PubMed:11564694};
CC         KM=19 uM for tryptophan (in the presence of choline chloride)
CC         {ECO:0000269|PubMed:11564694};
CC         KM=100.5 uM for L-leucine {ECO:0000269|PubMed:12225859};
CC         KM=295 uM for glutamine (in the presence of NaCl)
CC         {ECO:0000269|PubMed:10903140};
CC         KM=236 uM for leucine (in the presence of NaCl)
CC         {ECO:0000269|PubMed:10903140};
CC         KM=120 uM for arginine (in the presence of NaCl)
CC         {ECO:0000269|PubMed:10903140};
CC         KM=138 uM for arginine (in the absence of NaCl)
CC         {ECO:0000269|PubMed:10903140};
CC         Vmax=23878 pmol/min/mg enzyme for L-leucine
CC         {ECO:0000269|PubMed:12225859};
CC         Note=Km and Vmax values in PubMed:11564694 and PubMed:12225859 were
CC         determined for the heterodimer SLC7A5/LAT1 and SLC3A2/4F2hc.;
CC   -!- SUBUNIT: Disulfide-linked heterodimer with a non-glycosylated light
CC       chain (SLC7A5/LAT1, SLC7A6, SLC7A7, SLC7A8/LAT2, SLC7A10 or SLC7A11)
CC       (PubMed:11557028, PubMed:9829974, PubMed:9751058, PubMed:10574970,
CC       PubMed:10903140, PubMed:11311135, PubMed:30867591, PubMed:9751058,
CC       PubMed:12225859, PubMed:12117417, PubMed:15769744) (PubMed:34880232,
CC       PubMed:35352032). Interacts with TLCD3A/CT120 (PubMed:12270127).
CC       Interacts with ICAM1 (PubMed:12716892). Constitutively and specifically
CC       associates with beta-1 integrins (alpha-2/beta-1, alpha-3/beta-1,
CC       alpha-5/beta-1 and alpha-6/beta-1), but minimally with alpha-4/beta-1
CC       (PubMed:11696247). Interacts with LAPTM4B; recruits SLC3A2 and
CC       SLC7A5/LAT1 to lysosomes to promote leucine uptake into these
CC       organelles and is required for mTORC1 activation (PubMed:25998567).
CC       {ECO:0000269|PubMed:10574970, ECO:0000269|PubMed:10903140,
CC       ECO:0000269|PubMed:11311135, ECO:0000269|PubMed:11389679,
CC       ECO:0000269|PubMed:11557028, ECO:0000269|PubMed:11564694,
CC       ECO:0000269|PubMed:11696247, ECO:0000269|PubMed:12117417,
CC       ECO:0000269|PubMed:12225859, ECO:0000269|PubMed:12270127,
CC       ECO:0000269|PubMed:12716892, ECO:0000269|PubMed:14603368,
CC       ECO:0000269|PubMed:15769744, ECO:0000269|PubMed:17724034,
CC       ECO:0000269|PubMed:25998567, ECO:0000269|PubMed:30867591,
CC       ECO:0000269|PubMed:34880232, ECO:0000269|PubMed:35352032,
CC       ECO:0000269|PubMed:9751058, ECO:0000269|PubMed:9829974,
CC       ECO:0000269|PubMed:9878049}.
CC   -!- SUBUNIT: (Microbial infection) Interacts with hepatitis C virus/HCV
CC       envelope glycoprotein E2; the interaction may facilitate viral entry
CC       into host cell. {ECO:0000269|PubMed:30341327}.
CC   -!- INTERACTION:
CC       P08195; O15354: GPR37; NbExp=3; IntAct=EBI-702356, EBI-15639515;
CC       P08195; Q01650: SLC7A5; NbExp=2; IntAct=EBI-702356, EBI-6138761;
CC       P08195; O52302: sepZ; Xeno; NbExp=5; IntAct=EBI-702356, EBI-14022357;
CC       P08195-1; Q01650: SLC7A5; NbExp=3; IntAct=EBI-11614088, EBI-6138761;
CC       P08195-4; Q9NX09: DDIT4; NbExp=3; IntAct=EBI-12832276, EBI-715104;
CC       P08195-4; Q15125: EBP; NbExp=3; IntAct=EBI-12832276, EBI-3915253;
CC       P08195-4; P21333-2: FLNA; NbExp=3; IntAct=EBI-12832276, EBI-9641086;
CC       P08195-4; P04792: HSPB1; NbExp=3; IntAct=EBI-12832276, EBI-352682;
CC       P08195-4; O60333-2: KIF1B; NbExp=3; IntAct=EBI-12832276, EBI-10975473;
CC       P08195-4; Q5T3J3: LRIF1; NbExp=3; IntAct=EBI-12832276, EBI-473196;
CC       P08195-4; P31153: MAT2A; NbExp=3; IntAct=EBI-12832276, EBI-1050743;
CC       P08195-4; Q9UPY5: SLC7A11; NbExp=3; IntAct=EBI-12832276, EBI-3843348;
CC       P08195-4; Q9UHI5: SLC7A8; NbExp=3; IntAct=EBI-12832276, EBI-13292283;
CC       P08195-4; O76024: WFS1; NbExp=3; IntAct=EBI-12832276, EBI-720609;
CC       P08195-4; Q96BH6; NbExp=3; IntAct=EBI-12832276, EBI-25872486;
CC   -!- SUBCELLULAR LOCATION: Apical cell membrane
CC       {ECO:0000269|PubMed:11742812}. Cell membrane
CC       {ECO:0000269|PubMed:11311135, ECO:0000269|PubMed:11389679,
CC       ECO:0000269|PubMed:11557028, ECO:0000269|PubMed:11564694,
CC       ECO:0000269|PubMed:12225859, ECO:0000269|PubMed:15769744,
CC       ECO:0000269|PubMed:16496379, ECO:0000269|PubMed:25998567,
CC       ECO:0000269|PubMed:3476959, ECO:0000269|PubMed:3480538,
CC       ECO:0000269|PubMed:9829974}; Single-pass type II membrane protein
CC       {ECO:0000269|PubMed:30867591}. Cell junction
CC       {ECO:0000250|UniProtKB:P10852}. Lysosome membrane
CC       {ECO:0000269|PubMed:25998567}. Melanosome
CC       {ECO:0000269|PubMed:17081065}. Basolateral cell membrane
CC       {ECO:0000250|UniProtKB:P10852}. Note=Localized at the plasma membrane
CC       when associated with SLC7A5/LAT1 or SLC7A8/LAT2 (PubMed:9751058,
CC       PubMed:11311135). Localized to the apical membrane of placental
CC       syncytiotrophoblastic cells (PubMed:11742812). Recruited to lysosomes
CC       by LAPTM4B (PubMed:25998567). Identified by mass spectrometry in
CC       melanosome fractions from stage I to stage IV (PubMed:17081065).
CC       Located selectively at cell-cell adhesion sites (By similarity).
CC       Colocalized with SLC7A8/LAT2 at the basolateral membrane of kidney
CC       proximal tubules and small intestine epithelia. Expressed in both
CC       luminal and abluminal membranes of brain capillary endothelial cells
CC       (By similarity). {ECO:0000250|UniProtKB:P10852,
CC       ECO:0000269|PubMed:11311135, ECO:0000269|PubMed:11742812,
CC       ECO:0000269|PubMed:17081065, ECO:0000269|PubMed:25998567,
CC       ECO:0000269|PubMed:9751058}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=5;
CC       Name=1;
CC         IsoId=P08195-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P08195-2; Sequence=VSP_037907;
CC       Name=3;
CC         IsoId=P08195-3; Sequence=VSP_037908;
CC       Name=4;
CC         IsoId=P08195-4; Sequence=VSP_037909;
CC       Name=5;
CC         IsoId=P08195-5; Sequence=VSP_061769;
CC   -!- TISSUE SPECIFICITY: Expressed ubiquitously in all tissues tested with
CC       highest levels detected in kidney, placenta and testis and weakest
CC       level in thymus. During gestation, expression in the placenta was
CC       significantly stronger at full-term than at the mid-trimester stage.
CC       Expressed in HUVECS and at low levels in resting peripheral blood T-
CC       lymphocytes and quiescent fibroblasts. Also expressed in fetal liver
CC       and in the astrocytic process of primary astrocytic gliomas. Expressed
CC       in retinal endothelial cells and in the intestinal epithelial cell line
CC       C2BBe1. {ECO:0000269|PubMed:11389679, ECO:0000269|PubMed:11557028,
CC       ECO:0000269|PubMed:11742812, ECO:0000269|PubMed:12716892,
CC       ECO:0000269|PubMed:14603368, ECO:0000269|PubMed:15980244,
CC       ECO:0000269|PubMed:16496379, ECO:0000269|PubMed:3265470,
CC       ECO:0000269|PubMed:3480538}.
CC   -!- INDUCTION: Expression is induced in resting peripheral blood T-
CC       lymphocytes following PHA stimulation. Expression increases at the time
CC       of maximal DNA synthesis, in fibroblasts stimulated to divide.
CC       Expression and the uptake of leucine is stimulated in mononuclear,
CC       cytotrophoblast-like choriocarcinoma cells by combined treatment with
CC       PMA and calcium ionophore. Up-regulated in response to hydrogen
CC       peroxide (PubMed:30341327). {ECO:0000269|PubMed:11742812,
CC       ECO:0000269|PubMed:30341327, ECO:0000269|PubMed:3265470,
CC       ECO:0000269|PubMed:3480538}.
CC   -!- INDUCTION: (Microbial infection) Up-regulated upon hepatitis C
CC       virus/HCV infection via NS3-A4 viral protein complex; the up-regulation
CC       is mediated by oxidative stress (PubMed:30341327). Up-regulation of the
CC       complex formed by SLC3A2 and SLC7A5/LAT1 upon hepatitis C virus/HCV
CC       infection (PubMed:30341327). {ECO:0000269|PubMed:30341327}.
CC   -!- PTM: Phosphorylation on Ser-406; Ser-408 or Ser-410 and on Ser-527 or
CC       Ser-531 by ecto-protein kinases favors heterotypic cell-cell
CC       interactions. {ECO:0000269|PubMed:19065266}.
CC   -!- MASS SPECTROMETRY: Mass=57944.93; Method=MALDI;
CC       Evidence={ECO:0000269|PubMed:11840567};
CC   -!- MISCELLANEOUS: Arginine uptake is inhibited by increasing
CC       concentrations of leucine in the presence of Na(+).
CC   -!- SIMILARITY: Belongs to the SLC3A transporter family. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; J02939; AAA52497.1; -; mRNA.
DR   EMBL; J02769; AAA51540.1; -; mRNA.
DR   EMBL; J03569; AAA35536.1; -; mRNA.
DR   EMBL; M21904; AAA35489.1; -; Genomic_DNA.
DR   EMBL; M21898; AAA35489.1; JOINED; Genomic_DNA.
DR   EMBL; M21899; AAA35489.1; JOINED; Genomic_DNA.
DR   EMBL; M21900; AAA35489.1; JOINED; Genomic_DNA.
DR   EMBL; M21901; AAA35489.1; JOINED; Genomic_DNA.
DR   EMBL; M21902; AAA35489.1; JOINED; Genomic_DNA.
DR   EMBL; M21903; AAA35489.1; JOINED; Genomic_DNA.
DR   EMBL; AB018010; BAA84649.1; -; mRNA.
DR   EMBL; AP001160; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471076; EAW74118.1; -; Genomic_DNA.
DR   EMBL; BC001061; AAH01061.2; -; mRNA.
DR   EMBL; BC003000; AAH03000.2; -; mRNA.
DR   EMBL; BE794697; -; NOT_ANNOTATED_CDS; mRNA.
DR   CCDS; CCDS31588.1; -. [P08195-5]
DR   CCDS; CCDS31589.1; -. [P08195-3]
DR   CCDS; CCDS31590.1; -. [P08195-2]
DR   CCDS; CCDS8039.2; -. [P08195-1]
DR   PIR; A28455; SAHU4F.
DR   RefSeq; NP_001012680.1; NM_001012662.2. [P08195-5]
DR   RefSeq; NP_001012682.1; NM_001012664.2. [P08195-3]
DR   RefSeq; NP_001013269.1; NM_001013251.2. [P08195-2]
DR   RefSeq; NP_002385.3; NM_002394.5. [P08195-1]
DR   PDB; 2DH2; X-ray; 2.10 A; A=212-630.
DR   PDB; 2DH3; X-ray; 2.80 A; A/B=212-630.
DR   PDB; 6IRS; EM; 3.30 A; A=1-630.
DR   PDB; 6IRT; EM; 3.50 A; A=1-630.
DR   PDB; 6JMQ; EM; 3.31 A; B=2-630.
DR   PDB; 6JMR; EM; 4.10 A; B=2-630.
DR   PDB; 6S8V; X-ray; 1.80 A; B/D=212-630.
DR   PDB; 7B00; EM; 3.98 A; B=102-630.
DR   PDB; 7CCS; EM; 6.20 A; A=2-630.
DR   PDB; 7CMH; EM; 3.40 A; A=2-630.
DR   PDB; 7CMI; EM; 2.90 A; A=2-630.
DR   PDB; 7DF1; X-ray; 2.81 A; A/B/C/D=212-630.
DR   PDB; 7DSK; EM; 2.90 A; A=2-630.
DR   PDB; 7DSL; EM; 2.90 A; A=2-630.
DR   PDB; 7DSN; EM; 3.10 A; A=2-630.
DR   PDB; 7DSQ; EM; 3.40 A; A=2-630.
DR   PDB; 7EPZ; EM; 3.40 A; A=2-630.
DR   PDB; 7P9U; EM; 3.70 A; A=2-630.
DR   PDB; 7P9V; EM; 3.40 A; A=2-630.
DR   PDBsum; 2DH2; -.
DR   PDBsum; 2DH3; -.
DR   PDBsum; 6IRS; -.
DR   PDBsum; 6IRT; -.
DR   PDBsum; 6JMQ; -.
DR   PDBsum; 6JMR; -.
DR   PDBsum; 6S8V; -.
DR   PDBsum; 7B00; -.
DR   PDBsum; 7CCS; -.
DR   PDBsum; 7CMH; -.
DR   PDBsum; 7CMI; -.
DR   PDBsum; 7DF1; -.
DR   PDBsum; 7DSK; -.
DR   PDBsum; 7DSL; -.
DR   PDBsum; 7DSN; -.
DR   PDBsum; 7DSQ; -.
DR   PDBsum; 7EPZ; -.
DR   PDBsum; 7P9U; -.
DR   PDBsum; 7P9V; -.
DR   AlphaFoldDB; P08195; -.
DR   SMR; P08195; -.
DR   BioGRID; 112411; 415.
DR   CORUM; P08195; -.
DR   IntAct; P08195; 113.
DR   MINT; P08195; -.
DR   STRING; 9606.ENSP00000367123; -.
DR   GuidetoPHARMACOLOGY; 890; -.
DR   CAZy; GH13; Glycoside Hydrolase Family 13.
DR   TCDB; 2.A.3.8.18; the amino acid-polyamine-organocation (apc) family.
DR   TCDB; 8.A.9.2.2; the rbat transport accessory protein (rbat) family.
DR   GlyConnect; 984; 54 N-Linked glycans (3 sites).
DR   GlyCosmos; P08195; 4 sites, 51 glycans.
DR   GlyGen; P08195; 6 sites, 51 N-linked glycans (3 sites), 1 O-linked glycan (1 site).
DR   iPTMnet; P08195; -.
DR   MetOSite; P08195; -.
DR   PhosphoSitePlus; P08195; -.
DR   SwissPalm; P08195; -.
DR   BioMuta; SLC3A2; -.
DR   DMDM; 257051063; -.
DR   EPD; P08195; -.
DR   jPOST; P08195; -.
DR   MassIVE; P08195; -.
DR   MaxQB; P08195; -.
DR   PaxDb; P08195; -.
DR   PeptideAtlas; P08195; -.
DR   PRIDE; J3KPF3; -.
DR   ProteomicsDB; 52082; -. [P08195-1]
DR   ProteomicsDB; 52083; -. [P08195-2]
DR   ProteomicsDB; 52084; -. [P08195-3]
DR   ProteomicsDB; 52085; -. [P08195-4]
DR   ABCD; P08195; 54 sequenced antibodies.
DR   Antibodypedia; 15042; 1196 antibodies from 46 providers.
DR   DNASU; 6520; -.
DR   Ensembl; ENST00000338663.12; ENSP00000340815.7; ENSG00000168003.19. [P08195-2]
DR   Ensembl; ENST00000377889.6; ENSP00000367121.2; ENSG00000168003.19. [P08195-3]
DR   Ensembl; ENST00000377890.6; ENSP00000367122.2; ENSG00000168003.19. [P08195-1]
DR   Ensembl; ENST00000377891.6; ENSP00000367123.2; ENSG00000168003.19. [P08195-5]
DR   Ensembl; ENST00000538084.2; ENSP00000440001.2; ENSG00000168003.19. [P08195-4]
DR   Ensembl; ENST00000544377.2; ENSP00000442135.2; ENSG00000168003.19. [P08195-2]
DR   Ensembl; ENST00000680631.1; ENSP00000506006.1; ENSG00000168003.19. [P08195-2]
DR   Ensembl; ENST00000681657.1; ENSP00000505110.1; ENSG00000168003.19. [P08195-2]
DR   GeneID; 6520; -.
DR   KEGG; hsa:6520; -.
DR   MANE-Select; ENST00000338663.12; ENSP00000340815.7; NM_001013251.3; NP_001013269.1. [P08195-2]
DR   UCSC; uc001nwd.4; human. [P08195-1]
DR   AGR; HGNC:11026; -.
DR   CTD; 6520; -.
DR   DisGeNET; 6520; -.
DR   GeneCards; SLC3A2; -.
DR   HGNC; HGNC:11026; SLC3A2.
DR   HPA; ENSG00000168003; Low tissue specificity.
DR   MIM; 158070; gene.
DR   neXtProt; NX_P08195; -.
DR   OpenTargets; ENSG00000168003; -.
DR   PharmGKB; PA35894; -.
DR   VEuPathDB; HostDB:ENSG00000168003; -.
DR   eggNOG; KOG0471; Eukaryota.
DR   GeneTree; ENSGT00940000156646; -.
DR   HOGENOM; CLU_006462_9_0_1; -.
DR   InParanoid; P08195; -.
DR   OrthoDB; 4266085at2759; -.
DR   PhylomeDB; P08195; -.
DR   TreeFam; TF314498; -.
DR   BioCyc; MetaCyc:ENSG00000168003-MON; -.
DR   PathwayCommons; P08195; -.
DR   Reactome; R-HSA-210991; Basigin interactions.
DR   Reactome; R-HSA-352230; Amino acid transport across the plasma membrane.
DR   Reactome; R-HSA-5660862; Defective SLC7A7 causes lysinuric protein intolerance (LPI).
DR   Reactome; R-HSA-71240; Tryptophan catabolism.
DR   SABIO-RK; P08195; -.
DR   SignaLink; P08195; -.
DR   BioGRID-ORCS; 6520; 194 hits in 1175 CRISPR screens.
DR   ChiTaRS; SLC3A2; human.
DR   EvolutionaryTrace; P08195; -.
DR   GeneWiki; SLC3A2; -.
DR   GenomeRNAi; 6520; -.
DR   Pharos; P08195; Tbio.
DR   PRO; PR:P08195; -.
DR   Proteomes; UP000005640; Chromosome 11.
DR   RNAct; P08195; protein.
DR   Bgee; ENSG00000168003; Expressed in islet of Langerhans and 204 other tissues.
DR   ExpressionAtlas; P08195; baseline and differential.
DR   Genevisible; P08195; HS.
DR   GO; GO:1990184; C:amino acid transport complex; IDA:UniProtKB.
DR   GO; GO:0070161; C:anchoring junction; IEA:UniProtKB-SubCell.
DR   GO; GO:0016324; C:apical plasma membrane; IDA:ARUK-UCL.
DR   GO; GO:0044225; C:apical pole of neuron; IEA:Ensembl.
DR   GO; GO:0009925; C:basal plasma membrane; ISS:ARUK-UCL.
DR   GO; GO:0016323; C:basolateral plasma membrane; IDA:ARUK-UCL.
DR   GO; GO:0009986; C:cell surface; IDA:UniProtKB.
DR   GO; GO:0070062; C:extracellular exosome; HDA:UniProtKB.
DR   GO; GO:0005765; C:lysosomal membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0042470; C:melanosome; IEA:UniProtKB-SubCell.
DR   GO; GO:0016020; C:membrane; HDA:UniProtKB.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005886; C:plasma membrane; IDA:UniProtKB.
DR   GO; GO:0045202; C:synapse; IEA:Ensembl.
DR   GO; GO:0015173; F:aromatic amino acid transmembrane transporter activity; IGI:ARUK-UCL.
DR   GO; GO:0045296; F:cadherin binding; HDA:BHF-UCL.
DR   GO; GO:0005432; F:calcium:sodium antiporter activity; TAS:UniProtKB.
DR   GO; GO:0003725; F:double-stranded RNA binding; IDA:MGI.
DR   GO; GO:0015180; F:L-alanine transmembrane transporter activity; IGI:ARUK-UCL.
DR   GO; GO:0015190; F:L-leucine transmembrane transporter activity; IGI:ARUK-UCL.
DR   GO; GO:0015175; F:neutral L-amino acid transmembrane transporter activity; IGI:ARUK-UCL.
DR   GO; GO:0003723; F:RNA binding; HDA:UniProtKB.
DR   GO; GO:0006865; P:amino acid transport; TAS:UniProtKB.
DR   GO; GO:0006816; P:calcium ion transport; NAS:UniProtKB.
DR   GO; GO:0005975; P:carbohydrate metabolic process; IEA:InterPro.
DR   GO; GO:0015818; P:isoleucine transport; IDA:UniProtKB.
DR   GO; GO:1904273; P:L-alanine import across plasma membrane; IGI:ARUK-UCL.
DR   GO; GO:1902024; P:L-histidine transport; IDA:UniProtKB.
DR   GO; GO:1903801; P:L-leucine import across plasma membrane; IGI:ARUK-UCL.
DR   GO; GO:0098713; P:leucine import across plasma membrane; IGI:ARUK-UCL.
DR   GO; GO:0015820; P:leucine transport; IDA:UniProtKB.
DR   GO; GO:0015821; P:methionine transport; IDA:UniProtKB.
DR   GO; GO:0015823; P:phenylalanine transport; IDA:UniProtKB.
DR   GO; GO:0015824; P:proline transport; IDA:UniProtKB.
DR   GO; GO:0043330; P:response to exogenous dsRNA; IMP:MGI.
DR   GO; GO:0070327; P:thyroid hormone transport; IDA:UniProtKB.
DR   GO; GO:0015827; P:tryptophan transport; IDA:UniProtKB.
DR   GO; GO:0015828; P:tyrosine transport; IDA:UniProtKB.
DR   GO; GO:0015829; P:valine transport; IDA:UniProtKB.
DR   GO; GO:0046718; P:viral entry into host cell; IMP:UniProtKB.
DR   CDD; cd11345; AmyAc_SLC3A2; 1.
DR   Gene3D; 3.20.20.80; Glycosidases; 1.
DR   Gene3D; 2.60.40.1180; Golgi alpha-mannosidase II; 1.
DR   InterPro; IPR006047; Glyco_hydro_13_cat_dom.
DR   InterPro; IPR013780; Glyco_hydro_b.
DR   InterPro; IPR017853; Glycoside_hydrolase_SF.
DR   InterPro; IPR042280; SLC3A2.
DR   InterPro; IPR031984; SLC3A2_N.
DR   PANTHER; PTHR46673; 4F2 CELL-SURFACE ANTIGEN HEAVY CHAIN; 1.
DR   PANTHER; PTHR46673:SF1; 4F2 CELL-SURFACE ANTIGEN HEAVY CHAIN; 1.
DR   Pfam; PF00128; Alpha-amylase; 1.
DR   Pfam; PF16028; SLC3A2_N; 1.
DR   PRINTS; PR02045; F138DOMAIN.
DR   SMART; SM00642; Aamy; 1.
DR   SUPFAM; SSF51445; (Trans)glycosidases; 1.
DR   SUPFAM; SSF51011; Glycosyl hydrolase domain; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Alternative splicing; Amino-acid transport;
KW   Cell junction; Cell membrane; Direct protein sequencing; Disulfide bond;
KW   Glycoprotein; Isopeptide bond; Lysosome; Membrane; Phosphoprotein;
KW   Reference proteome; Signal-anchor; Transmembrane; Transmembrane helix;
KW   Transport; Ubl conjugation.
FT   CHAIN           1..630
FT                   /note="4F2 cell-surface antigen heavy chain"
FT                   /id="PRO_0000064383"
FT   TOPO_DOM        102..184
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000269|PubMed:30867591"
FT   TRANSMEM        185..205
FT                   /note="Helical; Signal-anchor for type II membrane protein"
FT                   /evidence="ECO:0000269|PubMed:30867591"
FT   TOPO_DOM        206..630
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000269|PubMed:30867591"
FT   REGION          15..39
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   MOD_RES         1
FT                   /note="N-acetylmethionine"
FT                   /evidence="ECO:0000269|Ref.10, ECO:0007744|PubMed:22814378"
FT   MOD_RES         103
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         106
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000250|UniProtKB:Q794F9"
FT   MOD_RES         134
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         165
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:19690332,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         406
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000305|PubMed:19065266"
FT   MOD_RES         408
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000305|PubMed:19065266"
FT   MOD_RES         410
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000305|PubMed:19065266"
FT   MOD_RES         527
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000305|PubMed:19065266"
FT   MOD_RES         531
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000305|PubMed:19065266"
FT   CARBOHYD        365
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:12754519,
FT                   ECO:0000269|PubMed:19159218, ECO:0000269|PubMed:19349973,
FT                   ECO:0000269|PubMed:30867591, ECO:0000269|PubMed:34880232,
FT                   ECO:0000269|PubMed:35352032, ECO:0007744|PDB:6IRS,
FT                   ECO:0007744|PDB:7EPZ, ECO:0007744|PDB:7P9V"
FT   CARBOHYD        381
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:12754519,
FT                   ECO:0000269|PubMed:16335952, ECO:0000269|PubMed:19159218,
FT                   ECO:0000269|PubMed:19349973, ECO:0000269|PubMed:30867591,
FT                   ECO:0000269|PubMed:34880232, ECO:0000269|PubMed:35352032,
FT                   ECO:0007744|PDB:6IRS, ECO:0007744|PDB:7EPZ,
FT                   ECO:0007744|PDB:7P9V"
FT   CARBOHYD        424
FT                   /note="N-linked (GlcNAc...) (complex) asparagine"
FT                   /evidence="ECO:0000269|PubMed:12754519,
FT                   ECO:0000269|PubMed:16335952, ECO:0000269|PubMed:19139490,
FT                   ECO:0000269|PubMed:19349973, ECO:0000269|PubMed:30867591,
FT                   ECO:0000269|PubMed:34880232, ECO:0000269|PubMed:35352032,
FT                   ECO:0007744|PDB:6IRS, ECO:0007744|PDB:7EPZ,
FT                   ECO:0007744|PDB:7P9V"
FT   CARBOHYD        506
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:19159218,
FT                   ECO:0000269|PubMed:19349973, ECO:0000269|PubMed:30867591,
FT                   ECO:0000269|PubMed:34880232, ECO:0000269|PubMed:35352032,
FT                   ECO:0007744|PDB:6IRS, ECO:0007744|PDB:7EPZ,
FT                   ECO:0007744|PDB:7P9V"
FT   DISULFID        210
FT                   /note="Interchain (with C-164 in SLC7A5 and C-158 in
FT                   SLC7A11)"
FT                   /evidence="ECO:0000269|PubMed:30867591,
FT                   ECO:0000269|PubMed:35352032, ECO:0000305|PubMed:17724034,
FT                   ECO:0007744|PDB:7EPZ"
FT   CROSSLNK        147
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in ubiquitin)"
FT   CROSSLNK        166
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:25114211"
FT   VAR_SEQ         1..101
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:11557028,
FT                   ECO:0000303|PubMed:3036867, ECO:0000303|PubMed:3476959,
FT                   ECO:0000303|PubMed:3480538"
FT                   /id="VSP_037907"
FT   VAR_SEQ         38..99
FT                   /note="Missing (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:15489334"
FT                   /id="VSP_037908"
FT   VAR_SEQ         39..98
FT                   /note="LGSHCVAQTGLELLASGDPLPSASQNAEMIETGSDCVTQAGLQLLASSDPPA
FT                   LASKNAEV -> TGSDCVTQAGLQLLASSDPPALASKNAEVTVETGFHHVSQADIEFLT
FT                   SIDPTASASGSAGI (in isoform 5)"
FT                   /id="VSP_061769"
FT   VAR_SEQ         98
FT                   /note="V -> VTETGFHHVSQADIEFLTSIDPTASASGSAGI (in isoform
FT                   4)"
FT                   /evidence="ECO:0000303|Ref.11"
FT                   /id="VSP_037909"
FT   MUTAGEN         182
FT                   /note="R->A,E,K,L: Strongly decreased leucine transport
FT                   activity."
FT                   /evidence="ECO:0000269|PubMed:30867591"
FT   MUTAGEN         210
FT                   /note="C->S: Abolishes dimerization, leucine uptake and
FT                   interaction with beta-1 integrins."
FT                   /evidence="ECO:0000269|PubMed:11696247,
FT                   ECO:0000269|PubMed:17724034, ECO:0000269|PubMed:9829974"
FT   MUTAGEN         234..630
FT                   /note="Missing: Nearly abolishes leucine transport
FT                   activity."
FT                   /evidence="ECO:0000269|PubMed:30867591"
FT   MUTAGEN         431
FT                   /note="C->S: No effect on dimerization, leucine uptake or
FT                   interaction with beta-1 integrins."
FT                   /evidence="ECO:0000269|PubMed:11696247,
FT                   ECO:0000269|PubMed:9829974"
FT   MUTAGEN         532
FT                   /note="K->E: Strongly decreased leucine transport
FT                   activity."
FT                   /evidence="ECO:0000269|PubMed:30867591"
FT   CONFLICT        137
FT                   /note="G -> E (in Ref. 4; AAA35536)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        158
FT                   /note="A -> P (in Ref. 3; AAA51540)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        223
FT                   /note="A -> P (in Ref. 4; AAA35536)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        315
FT                   /note="E -> D (in Ref. 4; AAA35536)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        320
FT                   /note="S -> F (in Ref. 5; AAA35489)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        372
FT                   /note="E -> G (in Ref. 4; AAA35536)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        412..413
FT                   /note="GE -> PQ (in Ref. 4; AAA35536)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        465
FT                   /note="V -> L (in Ref. 4; AAA35536)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        481
FT                   /note="G -> P (in Ref. 4; AAA35536)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        549
FT                   /note="G -> E (in Ref. 5; AAA35489)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        609
FT                   /note="L -> P (in Ref. 4; AAA35536)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        612
FT                   /note="E -> G (in Ref. 4; AAA35536)"
FT                   /evidence="ECO:0000305"
FT   HELIX           167..173
FT                   /evidence="ECO:0007829|PDB:7CMI"
FT   HELIX           178..181
FT                   /evidence="ECO:0007829|PDB:7CMI"
FT   HELIX           183..206
FT                   /evidence="ECO:0007829|PDB:7CMI"
FT   HELIX           218..220
FT                   /evidence="ECO:0007829|PDB:6S8V"
FT   STRAND          224..227
FT                   /evidence="ECO:0007829|PDB:6S8V"
FT   HELIX           230..234
FT                   /evidence="ECO:0007829|PDB:6S8V"
FT   HELIX           236..238
FT                   /evidence="ECO:0007829|PDB:7CMI"
FT   HELIX           241..245
FT                   /evidence="ECO:0007829|PDB:6S8V"
FT   HELIX           248..253
FT                   /evidence="ECO:0007829|PDB:6S8V"
FT   STRAND          257..261
FT                   /evidence="ECO:0007829|PDB:6S8V"
FT   STRAND          265..267
FT                   /evidence="ECO:0007829|PDB:6S8V"
FT   TURN            272..274
FT                   /evidence="ECO:0007829|PDB:7DSK"
FT   STRAND          275..280
FT                   /evidence="ECO:0007829|PDB:6S8V"
FT   HELIX           282..284
FT                   /evidence="ECO:0007829|PDB:6S8V"
FT   HELIX           287..299
FT                   /evidence="ECO:0007829|PDB:6S8V"
FT   STRAND          303..307
FT                   /evidence="ECO:0007829|PDB:6S8V"
FT   TURN            310..313
FT                   /evidence="ECO:0007829|PDB:6S8V"
FT   STRAND          314..316
FT                   /evidence="ECO:0007829|PDB:6S8V"
FT   STRAND          319..321
FT                   /evidence="ECO:0007829|PDB:2DH3"
FT   HELIX           323..340
FT                   /evidence="ECO:0007829|PDB:6S8V"
FT   STRAND          344..347
FT                   /evidence="ECO:0007829|PDB:6S8V"
FT   HELIX           350..352
FT                   /evidence="ECO:0007829|PDB:6S8V"
FT   HELIX           356..370
FT                   /evidence="ECO:0007829|PDB:6S8V"
FT   STRAND          375..379
FT                   /evidence="ECO:0007829|PDB:6S8V"
FT   HELIX           385..392
FT                   /evidence="ECO:0007829|PDB:6S8V"
FT   STRAND          399..401
FT                   /evidence="ECO:0007829|PDB:6S8V"
FT   STRAND          403..405
FT                   /evidence="ECO:0007829|PDB:7DSQ"
FT   STRAND          406..408
FT                   /evidence="ECO:0007829|PDB:6S8V"
FT   HELIX           412..425
FT                   /evidence="ECO:0007829|PDB:6S8V"
FT   TURN            426..428
FT                   /evidence="ECO:0007829|PDB:6S8V"
FT   STRAND          431..433
FT                   /evidence="ECO:0007829|PDB:7CMI"
FT   STRAND          437..439
FT                   /evidence="ECO:0007829|PDB:2DH3"
FT   HELIX           441..443
FT                   /evidence="ECO:0007829|PDB:6S8V"
FT   HELIX           447..449
FT                   /evidence="ECO:0007829|PDB:6S8V"
FT   HELIX           450..457
FT                   /evidence="ECO:0007829|PDB:6S8V"
FT   STRAND          460..467
FT                   /evidence="ECO:0007829|PDB:6S8V"
FT   HELIX           470..472
FT                   /evidence="ECO:0007829|PDB:6S8V"
FT   HELIX           476..478
FT                   /evidence="ECO:0007829|PDB:6S8V"
FT   STRAND          479..481
FT                   /evidence="ECO:0007829|PDB:2DH2"
FT   STRAND          484..486
FT                   /evidence="ECO:0007829|PDB:2DH2"
FT   HELIX           493..495
FT                   /evidence="ECO:0007829|PDB:2DH3"
FT   HELIX           500..502
FT                   /evidence="ECO:0007829|PDB:2DH3"
FT   HELIX           505..507
FT                   /evidence="ECO:0007829|PDB:6S8V"
FT   HELIX           509..513
FT                   /evidence="ECO:0007829|PDB:6S8V"
FT   HELIX           519..530
FT                   /evidence="ECO:0007829|PDB:6S8V"
FT   HELIX           534..538
FT                   /evidence="ECO:0007829|PDB:6S8V"
FT   STRAND          540..543
FT                   /evidence="ECO:0007829|PDB:6S8V"
FT   STRAND          547..549
FT                   /evidence="ECO:0007829|PDB:7CMI"
FT   STRAND          550..556
FT                   /evidence="ECO:0007829|PDB:6S8V"
FT   STRAND          558..560
FT                   /evidence="ECO:0007829|PDB:7CMI"
FT   STRAND          562..568
FT                   /evidence="ECO:0007829|PDB:6S8V"
FT   STRAND          570..572
FT                   /evidence="ECO:0007829|PDB:6S8V"
FT   HELIX           580..582
FT                   /evidence="ECO:0007829|PDB:6S8V"
FT   HELIX           585..587
FT                   /evidence="ECO:0007829|PDB:2DH2"
FT   STRAND          591..603
FT                   /evidence="ECO:0007829|PDB:6S8V"
FT   STRAND          607..610
FT                   /evidence="ECO:0007829|PDB:6S8V"
FT   HELIX           611..613
FT                   /evidence="ECO:0007829|PDB:6S8V"
FT   STRAND          621..626
FT                   /evidence="ECO:0007829|PDB:6S8V"
FT   INIT_MET        P08195-2:1
FT                   /note="Removed"
FT                   /evidence="ECO:0007744|PubMed:19413330,
FT                   ECO:0007744|PubMed:21406692, ECO:0007744|PubMed:22223895"
FT   MOD_RES         P08195-2:2
FT                   /note="N-acetylserine"
FT                   /evidence="ECO:0007744|PubMed:19413330,
FT                   ECO:0007744|PubMed:21406692, ECO:0007744|PubMed:22223895"
FT   MOD_RES         P08195-2:2
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:21406692"
SQ   SEQUENCE   630 AA;  67994 MW;  AE427F8204CC10B0 CRC64;
     MELQPPEASI AVVSIPRQLP GSHSEAGVQG LSAGDDSELG SHCVAQTGLE LLASGDPLPS
     ASQNAEMIET GSDCVTQAGL QLLASSDPPA LASKNAEVTG TMSQDTEVDM KEVELNELEP
     EKQPMNAASG AAMSLAGAEK NGLVKIKVAE DEAEAAAAAK FTGLSKEELL KVAGSPGWVR
     TRWALLLLFW LGWLGMLAGA VVIIVRAPRC RELPAQKWWH TGALYRIGDL QAFQGHGAGN
     LAGLKGRLDY LSSLKVKGLV LGPIHKNQKD DVAQTDLLQI DPNFGSKEDF DSLLQSAKKK
     SIRVILDLTP NYRGENSWFS TQVDTVATKV KDALEFWLQA GVDGFQVRDI ENLKDASSFL
     AEWQNITKGF SEDRLLIAGT NSSDLQQILS LLESNKDLLL TSSYLSDSGS TGEHTKSLVT
     QYLNATGNRW CSWSLSQARL LTSFLPAQLL RLYQLMLFTL PGTPVFSYGD EIGLDAAALP
     GQPMEAPVML WDESSFPDIP GAVSANMTVK GQSEDPGSLL SLFRRLSDQR SKERSLLHGD
     FHAFSAGPGL FSYIRHWDQN ERFLVVLNFG DVGLSAGLQA SDLPASASLP AKADLLLSTQ
     PGREEGSPLE LERLKLEPHE GLLLRFPYAA
//
